Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spanish-language pump training aims to close diabetes tech gap for latino youth

NCT ID NCT07720388

Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This trial tests whether a culturally tailored, Spanish-language onboarding and support program helps Latino youth aged 10–20 with type 1 diabetes adopt and consistently use the Medtronic MiniMed 780G automated insulin delivery system. Participants receive one-on-one nutrition support, a pump start class in Spanish, and regular virtual check-ins over eight months. The study asks whether this approach can improve technology adoption and health outcomes in a group that often faces barriers to using advanced diabetes devices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Culturally and linguistically tailored onboarding and support program for the Medtronic MiniMed 780G system
What this could lead to
If successful, this approach could help close the gap in technology adoption and improve blood sugar control in Latino youth with type 1 diabetes.
What could go wrong
This is a very small pilot study with only 15 participants, so results may not apply broadly. The program requires significant time and commitment from families.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 20 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 10 - 20 years old * Diagnosis of type 1 diabetes * Self-identify as Latino/Hispanic (determined via self-report and/or electronic health record) * Currently managing diabetes using any regimen, including multiple daily injections (MDI) or any non-Medtronic automated insulin delivery system * Willing to transition to and use the Medtronic MiniMed 780G system for the duration of the study Exclusion Criteria: * Current use of any Medtronic technology * More than 1 episode of diabetic ketoacidosis (DKA) within 12 months of study enrollment * Current pregnancy (self-reported), due to limited safety data for use of the Medtronic MiniMed 780G system during pregnancy * Presence of any significant medical condition that, in the opinion of the investigator, would interfere with study participation or data interpretation * Inability or unwillingness to use the Medtronic MiniMed 780G system for the duration of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 1 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 1 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barbara Davis Center

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.